BETHESDA, Md., April 20, 2015 /PRNewswire/ -- Northwest
Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a
biotechnology company developing DCVax® personalized
immune therapies for cancer, announced today that its clinical
programs with DCVax-L for Glioblastoma multiforme (GBM) brain
cancer, and with DCVax-Direct for all types of inoperable solid
tumors, will be featured in presentations on Monday, April 20, 2015, at the American
Association for Cancer Research Annual Meeting 2015 taking place in
Philadelphia.
Dr. Marnix Bosch, Chief Technical
Officer of NW Bio, will present a poster on the DCVax-L program,
entitled Prolonged Survival In Patients With Recurrent Glioblastoma
Multiforme Who Are Treated With Tumor Lysate-Pulsed Autologous
Dendritic Cells. This presentation will take place in Section 26 of
Halls B–E at the Pennsylvania
Convention Center from 1:00 p.m. to 5:00
p.m. on Monday, April 20. The presentation will include
further details about the subgroups within the Informational
Arm.
Dr. Bosch will also make an Exhibitor Spotlight Presentation on
Monday, April 20 from 3:00 p.m. to 3:30 p.m. in Exhibitor Spotlight
Theater B, located near the poster presentation area in Halls B–E
at the Pennsylvania Convention Center. Dr. Bosch will discuss
NW Bio's DCVax platform technology in a presentation entitled
Clinical Development of Dendritic Cell-Based Therapies for Cancer.
He will then return to the Company's poster presentation area to
complete the poster session.
The Clinical Trial Investigator at MD Anderson will present a
poster on the DCVax-Direct program, entitled Clinical and
Immunopathological Effects Following Image-Guided Intratumoral
Injection Of Activated, Autologous Dendritic Cells In Patients With
Advanced Solid Cancers. The poster will provide information about
immune responses in the patients in the Phase I trial overall, as
well as case study information. This presentation will take
place in Section 26 of Halls B--E of the Convention Center, from
1:00 p.m. to 5:00 p.m. on
Monday, April 20 (the same Hall and
time period as Dr. Bosch's poster presentation).
Both posters will be available on the Company's website at
www.nwbio.com.
The American Association for Cancer Research Annual Meeting 2015
highlights the latest discoveries in every area of cancer research,
and provides an opportunity for investigators to share their
insights. This year's meeting theme is "Bringing Cancer Discoveries
to Patients."
"We are pleased to have an opportunity to present information
about both our DCVax-L and DCVax-Direct clinical programs at this
prestigious research conference," commented Linda Powers, CEO of NW Bio. "In line with the
theme of this year's AACR meeting, we look forward to being able to
bring DCVax dendritic cell therapies to patients as a potential new
treatment option at the forefront of immune therapies for
cancer."
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively
than current treatments, without toxicities of the kind associated
with chemotherapies, and on a cost-effective basis, in both
the United States and Europe. The Company has a broad platform
technology for DCVax dendritic cell-based vaccines. The Company's
lead program is a 348-patient Phase III trial in newly diagnosed
glioblastoma multiforme (GBM). GBM is the most aggressive and
lethal form of brain cancer, and is an "orphan disease." The
Company is underway with a 60-patient Phase I/II trial of
DCVax-Direct for all inoperable solid tumors cancers, with a
primary efficacy endpoint of tumor regression. Enrollment has been
completed for the Phase I portion of the trial. The Company
previously received clearance from the FDA for a 612-patient Phase
III trial in prostate cancer. NWBio conducted a Phase I/II trial
with DCVax for metastatic ovarian cancer together with the
University of Pennsylvania. In
Germany, the Company has received
approval of a 5-year Hospital Exemption for the treatment of all
glioma (brain cancer) patients outside the clinical trial.
Disclaimer
Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "expect," "believe," "intend,"
"design," "plan," "continue," "may," "will," "anticipate," and
similar expressions are intended to identify forward-looking
statements. Actual results may differ materially from those
projected in any forward-looking statement. Specifically, there are
a number of important factors that could cause actual results to
differ materially from those anticipated, such as risks related to
the Company's ongoing ability to raise additional capital, risks
related to the Company's ability to enroll patients in its clinical
trials and complete the trials on a timely basis, uncertainties
about the clinical trials process, uncertainties about the timely
performance of third parties, risks related to whether the
Company's products will demonstrate safety and efficacy, risks
related to the Company's and Cognate's abilities to carry out the
intended manufacturing expansions contemplated in the Cognate
Agreements, risks related to the Company's ability to carry out the
Hospital Exemption program and risks related to possible
reimbursement and pricing. Additional information on these and
other factors, including Risk Factors, which could affect the
Company's results, is included in its Securities and Exchange
Commission ("SEC") filings. Finally, there may be other factors not
mentioned above or included in the Company's SEC filings that may
cause actual results to differ materially from those projected in
any forward-looking statement. You should not place undue reliance
on any forward-looking statements. The Company assumes no
obligation to update any forward-looking statements as a result of
new information, future events or developments, except as required
by securities laws.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nw-bio-featured-in-presentations-at-the-american-association-for-cancer-research-annual-meeting-300068337.html
SOURCE Northwest Biotherapeutics, Inc.